{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 22,
  "pageCount": 58,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "client_example",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-row structure to map strategic pillars to real-world examples and qualitative expert validation.",
  "elementsJson": [
    "headline_text",
    "icon_grid",
    "comparison_table",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/22",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "list",
      "text": "Improve drug features (e.g., dosage form, route of administration, safety, indication expansion)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0f4fa8a-2a52-4828-af1b-ba833ea73cf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "list",
      "text": "Invest in cutting-edge technology platforms",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6eeea54-1568-48b0-91c3-0ad35d56d792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Discover new drug targets for TAs with unmet needs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd0751b3-0eae-4c76-b879-9504b2bfd2e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Although developing new targets could be risky, it's worthy to take the risk because companies can avoid homogeneous competition and more importantly, it also boosts the progress of scientific development of the entire ecosystem ... - Science Lead, a Chinese CRO, May 2021",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-197bcd2ed2ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: *GCTTS: Giant Cell Tumor of Tendon Sheath (腱鞘巨细胞瘤) Source: Company websites, L.E.K. interviews and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6fd42ae-8366-4dcd-9068-439c12c71fb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.7,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "table",
      "text": "Business cases and Market feedback columns",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49751852-9060-4679-aa50-a0f5d143c777",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "In addition to new modalities, companies are also considering to tackle through discovering new targets, improving drug features and investing in cutting-edge technology platforms",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b774914-e033-486e-9621-c5ce1724af14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Development of More Innovative and Differentiated Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b42ac7ec-6233-488a-b4f0-01f71ef8e50b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "af95a5d1-ae9f-4241-ae12-e251101256d8",
      "evidence": "The components list several potential solutions or areas of focus for drug development, such as discovering new targets, improving drug features, and investing in cutting-edge technology platforms, which indicates a problem statement or areas for improvement.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}